Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PUNCH CD3: RBX2660 for Recurrent C. difficile Infection
NCT03244644Phase 3Completed
- Sponsor
- Rebiotix Inc.
- Start
- Jul 2017
- Primary completion
- Apr 2020
- Modality
- Live Biotherapeutic Products
- Countries
- 2
01
Overview
A Phase 3 trial of RBX2660 in Clostridioides difficile infection (CDI), sponsored by Rebiotix Inc.. Started Jul 2017; status: completed.
02
Drugs
RBX2660
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT03244644.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03244644.